Editorial, J Metabonomics Metabolites Vol: 1 Issue: 2
Metabolism and Metabonomics in Cancer Risk Assessment, Diagnosis, Prognosis and Treatment
M. Čuperlović-Culf1,2,3,4* | |
1National Research Council, Moncton, Canada | |
2Department of Chemistry and Biochemistry, Université de Moncton, Moncton, Canada | |
3Department of Chemistry and Biochemistry, Mount Allison University, Sackville, Canada | |
4Atlantic Cancer Research Institute, Moncton, Canada | |
Corresponding author : M. Cuperlovic-Culf, PhD National Research Council Canada, 100 des Aboiteaux street, Moncton, New Brunswick, E1A 7R1, Canada Tel: 506-861-0952; Fax: 506-851-3630 E-mail: miroslava.cuperlovic-culf@nrc-cnrc.gc.ca |
|
Received: November 14, 2012 Accepted: November 16, 2012 Published: November 19, 2012 | |
Citation: Cuperlovic-Culf M (2012) Metabolism and Metabonomics in Cancer Risk Assessment, Diagnosis, Prognosis and Treatment. J Metabonomics Metabolites 1:2. doi:10.4172/2325-9736.1000e108 |
Abstract
Metabolism and Metabonomics in Cancer Risk Assessment, Diagnosis, Prognosis and Treatment
Cancer is a genetic disease – changes to the cell’s DNA lead to malignant transformation and known hallmarks of cancer. Genetic or epigenetic mutations leading to altered expression levels and activation of oncogenes and oncosuppressor genes reprogram metabolism as well and this further promotes tumor progression. There are now many experimental and clinical proofs of the significance of cancer metabolic phenotype in cancer’s development, growth and metastasis.